MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for Intermediate AMD at ARVO 2026
Phase II trial (QA102-CS201) in 150 subjects with intermediate atrophic AMD, randomized 1:1:
1 to QA102 200mg, 400mg, or placebo BID for up to 15 months.
At 12 months, QA102 400mg reduced mean drusen volume change by 59.2% vs placebo.
Drusen volume growth rate reduced by 118.2% (p=0.017) and square-root GA area growth by 42.7% (p=0.026) in 400mg group.
Primary endpoint not statistically significant, but shows potential to slow intermediate dry AMD progression with acceptable safety.
Presented at ARVO 2026 in Denver; clinicaltrials.gov NCT05536752.
QA102 is first-in-class oral therapy; company advancing to next phase.